Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Ribo Life Science (6938 HK): Madrigal MASH Deal A Positive, But Still a Long Waiting Game

Equity Capital Markets

Suzhou Ribo Life Science / Equity Capital Markets

<ul>
<li>Ribo Life Sciences launched its Hongkong IPO aiming to raise up to HK$1,593.4M. The company plans to sell 27.5M shares at HK$57.97 per share.</li>
<li>Ribo Life Sciences is a biopharmaceutical company engaged in oligonucleotide research and development, with a focus on siRNA therapeutics.</li>
<li>Growth outlook does not quite justify the premium valuation of the company. We think the Ribo Life Science issue is slightly over priced. Investors can avoid the issue for now.</li>
</ul>


Ribo Life Sciences launched its Hongkong IPO aiming to raise up to HK$1,593.4M. The company plans to sell 27.5M shares at HK$57.97 per share.
Ribo Life Sciences is a biopharmaceutical company engaged in oligonucleotide research and development, with a focus on siRNA therapeutics.
Growth outlook does not quite justify the premium valuation of the company. We think the Ribo Life Science issue is slightly over priced. Investors can avoid the issue for now.


Ribo Life IPO: SiRNA Story Good, Issue Seems Slightly Overpriced Considering the Long Waiting Game